Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vadadustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 known ✓ | Q9GZT9 | 19/20 | 1.00 |
| ▸ | EGLN3 known ✓ | Q9H6Z9 | 8/20 | 1.00 |
| ▸ | FLT1 | P17948 | 7/20 | 1.00 |
| ▸ | VEGFA | P15692 | 6/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 1.00 |
| ▸ | BBOX1 | O75936 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | KDM8 | Q8N371 | 1/20 | 1.00 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 1.00 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vadadustat SCHEMBL1920738 | 1.00 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 | |
| Vadadustat SCHEMBL29405970 | 1.00 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 | |
| Vadadustat SCHEMBL1921291 | 0.94 | EGLN1 (0.89) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL14308517 | 0.91 | EGLN1 (0.83) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL21390798 | 0.90 | EGLN1 (0.82) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL15164149 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL1921390 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL16728915 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL30239851 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL23501769 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629357-B2 | Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer | AKEBIA THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | claimed |
| US-20250352527-A1 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | AKEBIA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4637791-A1 | SEVUPARIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | Modus Therapeutics AB (SE) | 2025-10-29 | — | — | EP | claimed |
| US-20250262229-A1 | APPLICATION OF PHD2 INHIBITOR IN PREPARATION OF DRUGS FOR PREVENTION AND TREATMENT OF PLATELET THROMBUS | NANKAI UNIVERSITY (CN) | 2025-08-21 | — | — | US | claimed |
| US-20250241925-A1 | METHODS OF P21 SUPPRESSION FOR BONE REGENERATION AND HEALING | UWM RESEARCH FOUNDATION, INC. | 2025-07-31 | — | — | US | claimed |
| US-12357628-B2 | Prevention and treatment of organ fibrosis | CORNELL UNIVERSITY (US) | 2025-07-15 | — | — | US | claimed |
| EP-4565233-A1 | TREATMENT FOR APLASTIC ANEMIA (AA) | Zydus Lifesciences Limited (IN) | 2025-06-11 | — | — | EP | claimed |
| US-20250171821-A1 | HIF-1 ACTIVATORS AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-05-29 | — | — | US | claimed |
| US-20220347167-A1 | A NEW TREATMENT FOR MEIBOMIAN GLAND DYSFUNCTION | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-11-03 | — | — | US | claimed |
| WO-2022183083-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022150623-A1 | COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF ANEMIA | AKEBIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| US-20220204451-A1 | METHOD FOR PRODUCING A VADADUSTAT INTERMEDIATE | KANEKA CORPORATION (JP) | 2022-06-30 | — | — | US | claimed |
| US-20220090083-A1 | TARGETING EGLN1 IN CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-03-24 | — | — | US | claimed |
| CN-114105866-A | Crystal form of hypoxia-inducible factor prolyl hydroxylase inhibitor and preparation method thereof | 广东东阳光药业有限公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2021263281-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CORDIOVASCULAR DISEASES | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220025324-A1 | METHODS OF PRODUCING VENOUS ANGIOBLASTS AND SINUSOIDAL ENDOTHELIAL CELL-LIKE CELLS AND COMPOSITIONS THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-27 | — | — | US | claimed |
| US-20220024874-A1 | MULTI-COMPONENT CRYSTALS OF AN ORALLY AVAILABLE HIF PROLYL HYDROXYLASE INHIBITOR | SANDOZ AG (CH) | 2022-01-27 | — | — | US | claimed |
| WO-2022018450-A1 | CRYSTALLINE FORMS OF VADADUSTAT AND METHODS FOR THEIR PREPARATION | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2022-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347167-A1 | A NEW TREATMENT FOR MEIBOMIAN GLAND DYSFUNCTION | HIF1AN, HIF1A, MTNR1A | EGLN1 11/4885EGLN3 4/4885FLT1 739/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | EGLN1 3/4885EGLN3 4/4885FLT1 144/4885 |
| US-20250352527-A1 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | HIF1A, HIF1AN, EGLN3 | EGLN1 6/4885EGLN3 3/4885FLT1 240/4885 |
| US-12357628-B2 | Prevention and treatment of organ fibrosis | MMP1, P4HA1, SERPINH1 | EGLN1 1390/4885EGLN3 196/4885FLT1 3575/4885 |
| US-20250241925-A1 | METHODS OF P21 SUPPRESSION FOR BONE REGENERATION AND HEALING | CDKN1A, BMP2, BCCIP | EGLN1 539/4885EGLN3 590/4885FLT1 3568/4885 |
| US-12629357-B2 | Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer | HIF1A, HIF1AN, EGLN3 | EGLN1 9/4885EGLN3 3/4885FLT1 155/4885 |
| US-20220024874-A1 | MULTI-COMPONENT CRYSTALS OF AN ORALLY AVAILABLE HIF PROLYL HYDROXYLASE INHIBITOR | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885EGLN3 2/4885FLT1 217/4885 |
| US-20220204451-A1 | METHOD FOR PRODUCING A VADADUSTAT INTERMEDIATE | MGMT, GNMT, DAO | EGLN1 1499/4885EGLN3 1170/4885FLT1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.